Literature DB >> 14516135

Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways.

M Ichinose1, H Sugiura, S Yamagata, A Koarai, M Tomaki, H Ogawa, Y Komaki, P J Barnes, K Shirato, T Hattori.   

Abstract

Reactive nitrogen species (RNS) have been reported to be involved in the inflammatory process in chronic obstructive pulmonary disease (COPD). However, there are no studies on the modulation of RNS in COPD. It was hypothesised that inhibition of xanthine oxidase (XO) might decrease RNS production in COPD airways through the suppression of superoxide anion production. Ten COPD and six healthy subjects participated in the study. The XO inhibitor allopurinol (300 mg x day(-1) p.o. for 4 weeks) was administered to COPD patients. RNS production in the airway was assessed by 3-nitrotyrosine immunoreactivity and enzymic activity of XO in induced sputum as well as by exhaled nitric oxide (eNO) concentration. XO activity in the airway was significantly elevated in COPD compared with healthy subjects. Allopurinol administration to COPD subjects significantly decreased XO activity and nitrotyrosine formation. In contrast, eNO concentration was significantly increased by allopurinol administration. These results suggest that oral administration of the xanthine oxidase inhibitor allopurinol reduces airway reactive nitrogen species production in chronic obstructive pulmonary disease subjects. This intervention may be useful in the future management of chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516135     DOI: 10.1183/09031936.03.00052002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  Xanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}.

Authors:  Sophie Gibbings; Nancy D Elkins; Hillary Fitzgerald; Janice Tiao; Mari E Weyman; Gayle Shibao; Mehdi A Fini; Richard M Wright
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

2.  Characterization of a fluorescent probe for imaging nitric oxide.

Authors:  Yohannes T Ghebremariam; Ngan F Huang; Swetha Kambhampati; Katharina S Volz; Gururaj G Joshi; Eric V Anslyn; John P Cooke
Journal:  J Vasc Res       Date:  2013-12-11       Impact factor: 1.934

3.  Redox-Dependent Calpain Signaling in Airway and Pulmonary Vascular Remodeling in COPD.

Authors:  Laszlo Kovacs; Yunchao Su
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 4.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

5.  Reducing agents decrease the oxidative burst and improve clinical outcomes in COPD patients: a randomised controlled trial on the effects of sulphurous thermal water inhalation.

Authors:  Marco Contoli; Giulia Gnesini; Giacomo Forini; Brunilda Marku; Alessia Pauletti; Anna Padovani; Paolo Casolari; Liliana Taurino; Andrea Ferraro; Milva Chicca; Adalberto Ciaccia; Alberto Papi; Silvano Pinamonti
Journal:  ScientificWorldJournal       Date:  2013-12-23

6.  Oxidative Stress and Therapeutic Development in Lung Diseases.

Authors:  Leah Villegas; Timothy Stidham; Eva Nozik-Grayck
Journal:  J Pulm Respir Med       Date:  2014-07-15

Review 7.  The role of pulmonary arterial stiffness in COPD.

Authors:  Jonathan R Weir-McCall; Allan D Struthers; Brian J Lipworth; J Graeme Houston
Journal:  Respir Med       Date:  2015-06-12       Impact factor: 3.415

Review 8.  Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review.

Authors:  Hamad Ghaleb Dailah
Journal:  Molecules       Date:  2022-08-28       Impact factor: 4.927

Review 9.  Oxidative stress-based therapeutics in COPD.

Authors:  Peter J Barnes
Journal:  Redox Biol       Date:  2020-04-20       Impact factor: 11.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.